MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414973 | Name: Piperaquine Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piperaquine Free Base is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine.

Chemical Structure

Piperaquine Free Base
Piperaquine Free Base
CAS#4085-31-8 (free base)

Theoretical Analysis

MedKoo Cat#: 414973

Name: Piperaquine Free Base

CAS#: 4085-31-8 (free base)

Chemical Formula: C29H32Cl2N6

Exact Mass: 534.2066

Molecular Weight: 535.52

Elemental Analysis: C, 65.04; H, 6.02; Cl, 13.24; N, 15.69

Price and Availability

Size Price Availability Quantity
10mg USD 390.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 1,025.00 2 Weeks
100mg USD 1,550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
4085-31-8 (free base); 911061-10-4 (tetraphosphate); 85547-56-4 (phosphate)
Synonym
Piperaquine Free Base; BRN0905079; BRN-0905079; BRN 0905079
IUPAC/Chemical Name
1,3-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)propane
InChi Key
UCRHFBCYFMIWHC-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2
SMILES Code
Clc(cc1)cc2c1c(N3CCN(CC3)CCCN4CCN(c(ccn5)c6c5cc(Cl)cc6)CC4)ccn2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 535.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ba Konko Ciré EH, Roh ME, Diallo A, Gadiaga T, Seck A, Thiam S, Gaye S, Diallo I, Lo AC, Diouf E, Ba OG, Gueye AB, Fogelson A, Wu X, Milligan P, Kibuka T, Hama M, Eckert E, Thwing J, Bennett A, Gosling R, Hwang J, Sene D, Ba F, Cissé B, Sturm-Ramirez K, Hsiang MS, Ndiaye JL. Mass drug administration to reduce malaria incidence in a low-to-moderate endemic setting: short-term impact results from a cluster randomised controlled trial in Senegal. medRxiv [Preprint]. 2024 Jul 18:2024.07.17.24310593. doi: 10.1101/2024.07.17.24310593. PMID: 39072042; PMCID: PMC11275686. 2: Rosado J, Fola AA, Cojean S, Sarrasin V, Coppée R, Zaffaroulah R, Bouzayene A, Cicéron L, Houzé L, Crudale R, Musset L, Thellier M, Pradines B, Clain J, Bailey JA, Houzé S; Investigation Study Group. Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African Plasmodium falciparum, 2016-2023: a genotype-phenotype association study. medRxiv [Preprint]. 2024 Jul 19:2024.07.17.24310448. doi: 10.1101/2024.07.17.24310448. PMID: 39072017; PMCID: PMC11275679. 3: Rosado J, Fola AA, Cojean S, Sarrasin V, Coppée R, Zaffaroulah R, Bouzayene A, Cicéron L, Maréchal C, Thaboulet G, Moissant C, Wallus L, Houzé L, Imbert N, Crudale R, Musset L, Thellier M, Pradines B, Clain J, Bailey JA, Houzé S, Group IS. Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African Plasmodium falciparum, 2016-2023: a genotype- phenotype association study. Res Sq [Preprint]. 2024 Jul 19:rs.3.rs-4763649. doi: 10.21203/rs.3.rs-4763649/v1. PMID: 39070647; PMCID: PMC11276023. 4: Zhao W, Xiang Z, Zeng W, Qin Y, Pan M, Wu Y, Duan M, Mou Y, Liang T, Zhang Y, Liu C, Tang X, Huang Y, Yang G, Cui L, Yang Z. Association study of Plasmodium falciparum Acetyl-CoA Synthetase Mutations S868G and V949I with antimalarial drugs. bioRxiv [Preprint]. 2024 Jul 11:2024.07.10.602966. doi: 10.1101/2024.07.10.602966. PMID: 39026738; PMCID: PMC11257502. 5: Ndiaye M, Diouf M, Mhamadi M, Djigal A, Manga IA, Sene C, Lelo S, Fall CB, Sylla K, Faye B. P. falciparum genetic markers associated with drug resistance from patients with treatment failure in the Southern part of Senegal in 2017. Int J Mol Epidemiol Genet. 2024 Jun 15;15(3):22-30. doi: 10.62347/RWLA6562. PMID: 39022192; PMCID: PMC11249792. 6: Rogerson SJ, Aitken EH. Malaria in pregnancy: baby steps. Curr Opin Infect Dis. 2024 Jul 11. doi: 10.1097/QCO.0000000000001037. Epub ahead of print. PMID: 39018104. 7: Mlugu EM, Minzi OMS, Johansson M, Kamuhabwa AAR, Aklillu E. Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy. BMC Pharmacol Toxicol. 2024 Jul 8;25(1):38. doi: 10.1186/s40360-024-00762-6. PMID: 38978151; PMCID: PMC11229336. 8: Hanboonkunupakarn B, Mukaka M, Jittamala P, Poovorawan K, Pongsuwan P, Stockdale L, Provstgaard-Morys S, Chotivanich K, Tarning J, Hoglund RM, Chimjinda N, Ewer K, Ramos-Lopez F, Day NPJ, Dondorp AM, Hill AV, White NJ, von Seidlein L, Pukrittayakamee S. A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults. NPJ Vaccines. 2024 Jul 6;9(1):124. doi: 10.1038/s41541-024-00920-1. PMID: 38971837; PMCID: PMC11227592. 9: Tong Y, Ratnasiri K, Hanif S, Nguyen AT, Roh ME, Dorsey G, Kakuru A, Jagannathan P, Benjamin-Chung J. Pathways through which intermittent preventive treatment for malaria in pregnancy influences child growth faltering: a mediation analysis. medRxiv [Preprint]. 2024 Jun 10:2024.06.09.24308656. doi: 10.1101/2024.06.09.24308656. PMID: 38947035; PMCID: PMC11213035. 10: Tran THT, Hien BTT, Dung NTL, Huong NT, Binh TT, Van Long N, Ton ND. Evaluation of Dihydroartemisinin-Piperaquine Efficacy and Molecular Markers in Uncomplicated Falciparum Patients: A Study across Binh Phuoc and Dak Nong, Vietnam. Medicina (Kaunas). 2024 Jun 20;60(6):1013. doi: 10.3390/medicina60061013. PMID: 38929629; PMCID: PMC11205605. 11: Kane J, Li X, Kumar S, Button-Simons KA, Vendrely Brenneman KM, Dahlhoff H, Sievert MAC, Checkley LA, Shoue DA, Singh PP, Abatiyow BA, Haile MT, Nair S, Reyes A, Tripura R, Peto TJ, Lek D, Mukherjee A, Kappe SHI, Dhorda M, Nkhoma SC, Cheeseman IH, Vaughan AM, Anderson TJC, Ferdig MT. A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance. mBio. 2024 Jul 17;15(7):e0080524. doi: 10.1128/mbio.00805-24. Epub 2024 Jun 24. PMID: 38912775; PMCID: PMC11253641. 12: Zhao W, Xiang Z, Zeng W, Qin Y, Pan M, Wu Y, Duan M, Mou Y, Liang T, Zhang Y, Liu C, Tang X, Huang Y, Yang G, Cui L, Yang Z. Acetyl-CoA Synthetase Mutations S868G and V949I Do Not Confer Resistance to Antimalarial Drugs in vitro in Plasmodium falciparum. bioRxiv [Preprint]. 2024 Jun 4:2024.06.03.597226. doi: 10.1101/2024.06.03.597226. PMID: 38895343; PMCID: PMC11185740. 13: Von Wowern F, Makenga G, Wellmann Thomsen S, Wellmann Thomsen L, Filtenborg Hocke E, Baraka V, Opot BH, Minja DTR, Lusingu JPA, Van-Geertruyden JP, Hansson H, Alifrangis M. Lack of selection of antimalarial drug resistance markers after intermittent preventive treatment of schoolchildren (IPTsc) against malaria in northeastern Tanzania. Int J Infect Dis. 2024 Sep;146:107102. doi: 10.1016/j.ijid.2024.107102. Epub 2024 Jun 13. PMID: 38876161. 14: Vanhove M, Schwabl P, Clementson C, Early AM, Laws M, Anthony F, Florimond C, Mathieu L, James K, Knox C, Singh N, Buckee CO, Musset L, Cox H, Niles-Robin R, Neafsey DE. Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana. PLoS Pathog. 2024 Jun 13;20(6):e1012013. doi: 10.1371/journal.ppat.1012013. PMID: 38870266; PMCID: PMC11206942. 15: Losada JC, Triana H, Vanegas E, Caro A, Rodríguez-López A, Espejo-Mojica AJ, Alméciga-Diaz CJ. Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB. Chembiochem. 2024 Aug 1;25(15):e202400081. doi: 10.1002/cbic.202400081. Epub 2024 Jul 16. PMID: 38830828. 16: Khalid Mohamed S, Khalid Mohamed D, Ahmed K, Saad F, Zurovac D. Health workers' adherence to malaria case management protocols in Northern Sudan: a qualitative study. Malar J. 2024 May 30;23(1):170. doi: 10.1186/s12936-024-04998-9. PMID: 38816778; PMCID: PMC11137897. 17: Opoku KB, Tompkins K, Waltmann A, Ciccone EJ, Bartlelt L, Andermann T, Chinkhumba J, Mathanga DP, Gutman JR, Juliano JJ. Impact of Sulfadoxine- Pyrimethamine and Dihydroartemisinin-Piperaquine as Intermittent Preventive Treatment in Pregnancy on Stool Antimicrobial Resistance Gene Abundance. Am J Trop Med Hyg. 2024 May 28;111(1):43-47. doi: 10.4269/ajtmh.23-0824. PMID: 38806022; PMCID: PMC11229632. 18: Brown N, da Silva C, Webb C, Matias D, Dias B, Cancio B, Silva M, Viegas R, Salvador C, Chivale N, Luis S, Arnaldo P, Zulawinska J, Moore CC, Nogueira F, Guler JL. Antimalarial resistance risk in Mozambique detected by a novel quadruplex droplet digital PCR assay. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0034624. doi: 10.1128/aac.00346-24. Epub 2024 May 21. PMID: 38771031; PMCID: PMC11232384. 19: Xie Y, Zhang Y, Lin F, Chen X, Xing J. The effect of malaria-induced alteration of metabolism on piperaquine disposition in Plasmodium yoelii infected mice and predicted in malaria patients. Int J Antimicrob Agents. 2024 Jul;64(1):107209. doi: 10.1016/j.ijantimicag.2024.107209. Epub 2024 May 17. PMID: 38761871. 20: Cheng K, Aitken EH, Hasang W, Meagher N, Price DJ, Madanitsa M, Mwapasa V, Phiri KS, Dodd J, Ter Kuile FO, Rogerson SJ. Intermittent preventive treatment with sulphadoxine-pyrimethamine but not dihydroartemisinin-piperaquine modulates the relationship between inflammatory markers and adverse pregnancy outcomes in Malawi. PLOS Glob Public Health. 2024 May 16;4(5):e0003198. doi: 10.1371/journal.pgph.0003198. PMID: 38753813; PMCID: PMC11098340.